Billing Codes

61369

Indium-labelled octreotide study (including single photon emission tomography when undertaken), if:(a) a gastro-entero-pancreatic endocrine tumour is suspected on the basis of biochemical evidence with negative or equivocal conventional imaging; or(b) both:(i) a surgically amenable gastro-entero-pancreatic endocrine tumour has been identified on the basis of conventional techniques; and(ii) the study is to exclude additional disease sites (R)

MBS fee
$2191.90
DVA fee
$2136.35
Category
Category 5 — Diagnostic Imaging
Status
Unchanged
Additional DVA rates
DI Fee
$2136.35
Full description

Indium-labelled octreotide study (including single photon emission tomography when undertaken), if:(a) a gastro-entero-pancreatic endocrine tumour is suspected on the basis of biochemical evidence with negative or equivocal conventional imaging; or(b) both:(i) a surgically amenable gastro-entero-pancreatic endocrine tumour has been identified on the basis of conventional techniques; and(ii) the study is to exclude additional disease sites (R)

Fee history

No recorded changes yet — history accumulates with each release.

Data sourced from Australian Government publications · Not an official government service